Unitaid transparency policy
Policy on ethics and conflict of interest for Unitaid
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Unitaid and medical oxygen
Universal Health Coverage
Pandemic prevention, preparedness and response
Building climate-resilient, sustainable, and low-carbon health supply chains: key priorities for collective action
Gonorrhea point-of-care diagnostics technology and market landscape
Screening and treatment of precancerous lesions for secondary prevention of cervical cancer
Landscape report on commodity and service delivery innovations for detection and management of pre-eclampsia
Medical oxygen innovation landscape
The untold story of dolutegravir: When climate impact goes hand-in-hand with access to better treatments
Antimalarial manufacturing in Africa: A call for regional action
Enabling a market-based approach to manufacturing quality-assured health products in Africa: A differentiated coordination approach
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Patent landscape: grazoprevir
Patent landscape: elbasvir
Patents and licenses on antiretrovirals: a snapshot
Malaria medicines technology and market landscape – 2nd edition
Malaria diagnostics market landscape – semi-annual update
Hepatitis C medicines technology and market landscape
Hepatitis C diagnostics technology landscape – 1st edition
HIV/AIDS diagnostics technology landscape – semi-annual update
